The country’s drug price regulator has reduced prices of eight medicines sold by leading pharma companies such as Cipla, Sun Pharma and Unichem by up to 85%, in one of the sharpest price cuts over the past few years. The prices of seven of these eight brands have been fixed by the drug price regulator for the first time. NPPA prescribes a price ceiling for drugs containing any of the 74 chemicals that are under price control to contain the cost of medication for consumers.
The maximum price for Cipla’s popular combination antibiotic, Ciplox TZ, has been cut by 74% from Rs 100.73 to Rs 25.7 (excluding taxes) for a 10-tablet strip. The price of Rexcin Pharmaceuticals’ popular burn ointment, Silverex AV cream, has been slashed by around 85% to Rs 25 for a 20-gm tube. The regulator has also slashed the price of Cosmo Life Sciences vitamin capsules Lycobal Forte by 88.7% to Rs 8.90 (excluding taxes) for 10 capsules. The other medicines whose prices have been cut include JB Remedies’ Nor-Tz tablets and Okassa Pharma’s Burn Heal cream.
Most of the medicines whose prices have been cut are combination drugs i.e. drugs that have more than one molecule. As per Indian laws, a combination drug that contains an ingredient that is under price control has to automatically conform to the price ceiling mandated by the drug price regulator. The drugmakers have to revise their prices within 15 days of the notification, failing which they could be penalised for overcharging consumers.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: